Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/celltrion-inc" target="_blank" data-smartkarma-citation="entities:991:1" rel="noopener">Celltrion Inc (068270 KS)</a> reported preliminary 2Q26 result, marking the highest Q2 performance in its history. Greater contribution from high-margin young products and structurally improved cost base drove 2Q26 performance.</li>
<li>Newer products including Remsima SC, Yuflyma, and Steqeyma continued to deliver strong growth across major markets, with the newer portfolio accounting for 60%+ of total revenue (versus 51% in 1Q26).</li>
<li>Major tender opportunities and continued momentum from newly launched products are expected to support stronger performance in 2H26. Thus, sales growth is expected to accelerate further.</li>
</ul>



Celltrion Inc (068270 KS) reported preliminary 2Q26 result, marking the highest Q2 performance in its history. Greater contribution from high-margin young products and structurally improved cost base drove 2Q26 performance.
Newer products including Remsima SC, Yuflyma, and Steqeyma continued to deliver strong growth across major markets, with the newer portfolio accounting for 60%+ of total revenue (versus 51% in 1Q26).
Major tender opportunities and continued momentum from newly launched products are expected to support stronger performance in 2H26. Thus, sales growth is expected to accelerate further.


Celltrion (068270 KS): New Products Drive Record High 2Q Performance; Growth to Accelerate in 2H

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Event-Driven

<ul>
<li>In this insight, I discuss the alpha generation through companies that announced share buybacks in the Korean stock market in May and June 2026.</li>
<li>I provide a list of 59 companies in the Korean stock market that have announced share buyback programs in the past two months.</li>
<li>There were eight companies with more than 300 billion won in market cap that announced share buybacks in the past two months with at least 1% of outstanding shares.</li>
</ul>


In this insight, I discuss the alpha generation through companies that announced share buybacks in the Korean stock market in May and June 2026.
I provide a list of 59 companies in the Korean stock market that have announced share buyback programs in the past two months.
There were eight companies with more than 300 billion won in market cap that announced share buybacks in the past two months with at least 1% of outstanding shares.


Alpha Generation Through Share Buybacks in Korea: Bi-Monthly (May & June 2026)

<ul>
<li><em><strong>Celltrion announced that it plans to cancel 9.11 million treasury shares (representing 3.9% of its outstanding shares) and worth about 1.7 trillion won on 1 April 2026.</strong></em></li>
<li>This marks the largest scale of treasury share cancellation in the company's history. From end of 2023 to 1 April 2026, Celltrion's outstanding shares are expected to decline by 7.4%.</li>
<li>Celltrion plans to increase the size of its cash dividends to 30% of its earnings (EBITDA-CAPEX) in the mid-to-long term, up from 22% in 2025.</li>
</ul>


Celltrion announced that it plans to cancel 9.11 million treasury shares (representing 3.9% of its outstanding shares) and worth about 1.7 trillion won on 1 April 2026.
This marks the largest scale of treasury share cancellation in the company's history. From end of 2023 to 1 April 2026, Celltrion's outstanding shares are expected to decline by 7.4%.
Celltrion plans to increase the size of its cash dividends to 30% of its earnings (EBITDA-CAPEX) in the mid-to-long term, up from 22% in 2025.


Celltrion: Cancellation of 1.7 Trillion Won of Treasury Shares

Thematic (Sector/Industry)

<ul>
<li>CSPC Pharmaceutical’s SYS6010 met primary endpoint in Phase 3 study as a monotherapy for NSCLC. Akeso’s ivonescimab demonstrates significant overall survival in Phase 3 trial for advanced biliary tract cancer.</li>
<li>Takeda Pharma secured FDA approval for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Astellas Pharma initiates global Phase 3 study evaluating ASP2138 for gastric cancers.</li>
<li>Hanmi Pharm outlicenses obesity drug candidate HM1732 to Genentech for a total deal value of $2.3B. SK Biopharmaceuticals entered an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven.</li>
</ul>


CSPC Pharmaceutical’s SYS6010 met primary endpoint in Phase 3 study as a monotherapy for NSCLC. Akeso’s ivonescimab demonstrates significant overall survival in Phase 3 trial for advanced biliary tract cancer.
Takeda Pharma secured FDA approval for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera. Astellas Pharma initiates global Phase 3 study evaluating ASP2138 for gastric cancers.
Hanmi Pharm outlicenses obesity drug candidate HM1732 to Genentech for a total deal value of $2.3B. SK Biopharmaceuticals entered an agreement to in-license opakalim, an investigational antiseizure medication, from Biohaven.


APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

<ul>
<li>Henlius Biotech is collaborating with Sandoz for commercialization of up to 10 biosimilars in ~$322M deal. Wuxi XDC achieved GMP release of its antibody bioconjugates production line at Singapore site.</li>
<li>Chugai Pharmaceutical signed an exclusive license agreement with GSK for the anti-dengue virus antibody AID351. Daiichi Sankyo’s Enhertu demonstrated PFS improvement as first-line treatment of NSCLC in Phase 3 trial.</li>
<li>Celltrion has launched IV formulation of Steqeyma in Japan. Eubiologics submitted an IND to the MFDS for domestic Phase 1 trial for its Alzheimer’s disease vaccine candidate, Padivax.</li>
</ul>


Henlius Biotech is collaborating with Sandoz for commercialization of up to 10 biosimilars in ~$322M deal. Wuxi XDC achieved GMP release of its antibody bioconjugates production line at Singapore site.
Chugai Pharmaceutical signed an exclusive license agreement with GSK for the anti-dengue virus antibody AID351. Daiichi Sankyo’s Enhertu demonstrated PFS improvement as first-line treatment of NSCLC in Phase 3 trial.
Celltrion has launched IV formulation of Steqeyma in Japan. Eubiologics submitted an IND to the MFDS for domestic Phase 1 trial for its Alzheimer’s disease vaccine candidate, Padivax.


APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion

South Korea

Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies.  The Company's main product is Abata cept which is for arthritis treatment

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Celltrion Inc (068270 KS)

Celltrion (068270 KS): New Products Drive Record High 2Q Performance; Growth to Accelerate in 2H

Celltrion reported record-breaking Q2 result, driven by high-margin new products and structurally improved cost base. 2H sales will outpace 1H,...

Tina Banerjee

Celltrion: Cancellation of 1.7 Trillion Won of Treasury Shares

Celltrion announced that it plans to cancel 9.11 million treasury shares (representing 3.9% of its outstanding shares) and worth about 1.7 trillion...

Douglas Kim

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Tina Banerjee

APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion

Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Celltrion (068270 KS): New Products Drive Record High 2Q Performance; Growth to Accelerate in 2H

​Celltrion reported record-breaking Q2 result, driven by high-margin new products and structurally improved cost base. 2H sales will outpace 1H,...

Tina Banerjee

Alpha Generation Through Share Buybacks in Korea: Bi-Monthly (May & June 2026)

​Analysis of alpha generation through share buybacks in Korean stock market, highlighting 59 companies with buyback programs in May and June 2026.

Douglas Kim

Celltrion: Cancellation of 1.7 Trillion Won of Treasury Shares

Celltrion announced that it plans to cancel 9.11 million treasury shares (representing 3.9% of its outstanding shares) and worth about 1.7 trillion...

Douglas Kim

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Tina Banerjee

APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion

Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....

Tina Banerjee

Celltrion reported record-breaking Q2 result, driven by high-margin new products and structurally improved cost base. 2H sales will outpace 1H,...

Analysis of alpha generation through share buybacks in Korean stock market, highlighting 59 companies with buyback programs in May and June 2026.